Lamassu BioTech

Bridging the Gap: Lamassu is revolutionizing drug development by leveraging innovative strategies to bridge academia and industry. Our talented team identifies novel therapeutics with strong scientific rationale and preclinical efficacy, ensuring a faster path to market approval. Together, we bring hope to patients waiting for life-saving treatments. Learn more at www.LamassuBioTech.com. ?#TranslationalResearch #MedicalBreakthroughs

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow #LamassuBioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.

#ThrowbackThursday - Earlier this year, in an exclusive column for cleveland.com, Lamassu Biotech CEO Gabi Hanna MD., wrote: "Few challenges loom larger for humanity than the fight against cancer. Cancer is an adversary that demands an approach that harnesses the latest technology and the best instincts of the human spirit – on a global scale. By leveraging the collective expertise of researchers, clinicians, policymakers, and industry leaders, we can usher in a new era of hope and healing for cancer patients worldwide." #cancer #biotech #innovation #publicprivatepartnerships #cancertreatment #sarcoma #medicine

Successful biotechnology and pharmaceutical companies require a comprehensive approach to identifying and advancing solutions to unmet needs in the healthcare market. Lamassu is privileged to have built strong relationships with some of the most accomplished and iconic brands and institutions in biotech.? #biotech #drugdevelopment #research #clinicaltrials #cancer #pancreatitis

Acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions in the United States. For patients suffering from this condition, this results in many hospitalizations, ineffective medications, long term complications, and lost time with their families and at work. Lamassu’s lead candidate, RABI-767, is a novel small molecule therapy for acute pancreatitis. It was developed at the Mayo Clinic by leading scientists, and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. Phase 1/2 trials are currently ongoing. #pancreatitis #research #drugdevelopment #healthcare

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow #LamassuBioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.

#ThrowbackThursday: Over the summer, Newsmax Media, Inc. featured a thoughtful piece profiling Lamassu’s “New Approach to Cancer Treatment.” As the article notes, our SA53 MDM2 inhibitor therapy is a new type of cancer therapy that could transform the treatment of many deadly cancers, especially those that have advanced or metastasized and do not respond to other therapies.

New Hope for Metastatic Cancer Treatment: P53 is a crucial tumor suppressor gene commonly mutated in human cancers. Its role in preventing tumor formation by inducing programmed cell death in response to cellular stress makes it a key target for cancer therapy. Lamassu’s SA53 MDM2 inhibitor is a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue. SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission.

THE LAMASSU METHOD: The approval of new medical treatments from the start of clinical trials to approval for the market can take on average over 10 years, according to most industry experts. Lamassu leverages innovative approaches to drive collaboration between academia and industry through translational research. We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline.

#ThrowbackThursday: The next administration must work to reduce the risks associated with biotech innovation, by creating stronger public-private partnerships that share the financial burden of early-stage research. Read Lamassu CEO Dr. Gabi Hanna’s recent op-ed in RealClearHealth. #innovation #drugdevelopment #cancer #cancerresearch #biotech #biotechnology